Recent Company News

• 12:25 PM ET Oct 19, 2025
  

  Daiichi Sankyo presents initial results from first-in-human phase 1/2 trial of DS-3939 at ESMO (¥3996.0000, 0)

• 12:21 PM ET Oct 19, 2025
  

  Daiichi Sankyo presents results from REJOICE-Ovarian01 trial of raludotatug deruxtecan at ESMO (¥3996.0000, 0)

• 06:53 AM ET Oct 19, 2025
  

  Daiichi Sankyo, AstraZeneca present results from TROPION-Breast02 trial of Datroway at ESMO

• 11:56 PM ET Oct 18, 2025
  

  Daiichi Sankyo presents results from DESTINY-Breast05 trial of ENHERTU at ESMO (¥3996.0000, 0)

• 11:51 PM ET Oct 18, 2025
  

  Daiichi Sankyo presents results from DESTINY-Breast11 trial of ENHERTU at ESMO (¥3996.0000, 0)

• 10:04 AM ET Oct 17, 2025
  

  Daiichi Sankyo announces initial results from sub-study of TROPION-PanTumor03 phase 2 trial for DATROWAY plus rilvegostomig (¥3996.0000, 0)

• 06:51 AM ET Oct 09, 2025
  

  Merck announces new research to be presented at the ESMO Congress 2025 ($86.40, 0.00)

• 10:48 PM ET Oct 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 02:48 AM ET Oct 07, 2025
  

  Daiichi Sankyo submits sNDA in Japan for ENHERTU in combination with pertuzumab for treatment of patients with HER2 positive metastatic breast cancer (¥4001.0000, 0)

• 12:00 AM ET Oct 07, 2025
  

  Daiichi Sankyo trades +2.4%; Datroway 1L TNBC results seen as strengthening oncology pipeline visibility (¥4006.0000, +101)